Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Profit After Tax (2022 - 2025)

BioXcel Therapeutics has reported Profit After Tax over the past 4 years, most recently at -$12.5 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$12.5 million for Q4 2025, down 15.53% from a year ago — trailing twelve months through Dec 2025 was -$69.9 million (down 17.28% YoY), and the annual figure for FY2025 was -$69.9 million, down 17.28%.
  • Profit After Tax for Q4 2025 was -$12.5 million at BioXcel Therapeutics, up from -$30.9 million in the prior quarter.
  • Over the last five years, Profit After Tax for BTAI hit a ceiling of -$7.3 million in Q1 2025 and a floor of -$54.8 million in Q4 2022.
  • Median Profit After Tax over the past 4 years was -$28.9 million (2024), compared with a mean of -$29.6 million.
  • Biggest five-year swings in Profit After Tax: soared 84.49% in 2024 and later plummeted 131.2% in 2025.
  • BioXcel Therapeutics' Profit After Tax stood at -$54.8 million in 2022, then skyrocketed by 59.39% to -$22.3 million in 2023, then soared by 51.21% to -$10.9 million in 2024, then decreased by 15.53% to -$12.5 million in 2025.
  • The last three reported values for Profit After Tax were -$12.5 million (Q4 2025), -$30.9 million (Q3 2025), and -$19.2 million (Q2 2025) per Business Quant data.